Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.63 - $3.08 $218,794 - $413,428
-134,230 Reduced 88.7%
17,101 $32,000
Q4 2023

Feb 09, 2024

BUY
$1.07 - $3.07 $161,924 - $464,586
151,331 New
151,331 $411,000
Q3 2022

Nov 10, 2022

SELL
$3.09 - $5.23 $1,421 - $2,405
-460 Reduced 92.93%
35 $0
Q2 2022

Aug 10, 2022

SELL
$2.58 - $4.99 $7,239 - $14,001
-2,806 Reduced 85.0%
495 $2,000
Q1 2022

May 12, 2022

SELL
$3.93 - $7.7 $729,742 - $1.43 Million
-185,685 Reduced 98.25%
3,301 $13,000
Q4 2021

Feb 10, 2022

BUY
$7.1 - $12.82 $371,053 - $669,986
52,261 Added 38.22%
188,986 $1.34 Million
Q3 2021

Nov 10, 2021

BUY
$7.64 - $12.49 $1.04 Million - $1.71 Million
136,725 New
136,725 $1.5 Million

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $26.9M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.